Tesamorelin Side Effects & Safety: What the FDA Label Says

Tesamorelin is unusual among the growth-hormone peptides for a simple reason: its side effects are not guesswork. Because it is an FDA-approved drug (sold as EGRIFTA SV), its safety profile is written down on a current prescribing label and was measured in placebo-controlled trials of more than 700 patients¹². That makes a tesamorelin side-effect article one of the few in this category where you can quote real rates instead of forum anecdote. This piece does exactly that — and is honest about the one limitation that follows: those rates come from a specific population (adults with HIV-associated lipodystrophy), so for the off-label, clinic-marketed use they are the best estimate available, not a guarantee.

The most common side effects (from the label)

Across the pivotal trials, the most commonly reported adverse reactions were hypersensitivity reactions (such as rash or hives), edema-related reactions (arthralgia, extremity pain, peripheral edema, carpal tunnel syndrome), elevated blood glucose, and injection-site reactions¹. The injection-site category — redness, itching, pain, and swelling at the abdominal injection — is the everyday complaint, and it is the same local reaction expected of any subcutaneously injected peptide. These are typically mild and managed with site rotation and standard injection hygiene.

It is worth being precise about how this data was generated. The 2 mg/vial EGRIFTA SV formulation delivers a 1.4 mg dose, and its safety was established on the earlier 1 mg/vial EGRIFTA (2 mg dose) studied in 543 patients during the 26-week placebo-controlled phase¹. So when you see a tesamorelin side-effect rate, it traces back to that 26-week randomized dataset — short-to-medium term, in a defined patient group.

Fluid retention: the GH-axis signature

The side effect that most reflects what tesamorelin actually does is fluid retention. Because the drug raises growth hormone and IGF-1, it can cause the classic 'too much GH' cluster: edema (swelling), arthralgia (joint aches), and carpal tunnel syndrome¹. The label flags this directly as a warning. The reassuring detail is that these reactions are described as either transient or resolving when treatment is stopped¹ — they are a signal of GH-axis activation, not permanent damage. This is the same mechanism behind the joint and water-retention complaints reported with sermorelin and the other GHRH peptides, just better documented here.

Blood sugar: the metabolic caution that needs monitoring

Growth hormone opposes insulin, so the most clinically important tesamorelin side effect is its effect on glucose. The label is specific: tesamorelin treatment can result in glucose intolerance, and in clinical trials the percentage of patients with elevated HbA1c (≥6.5%) from baseline to week 26 was 5% on EGRIFTA versus 1% on placebo, with an increased risk of developing diabetes relative to placebo¹. That is why the label instructs clinicians to evaluate glucose status before starting and during therapy¹. In the pivotal efficacy trial the visceral-fat benefit was achieved alongside an 81% rise in IGF-1³, and the metabolic literature on the drug emphasizes watching glucose and IGF-1 throughout treatment⁴⁵. The honest framing: this is a real, dose-relevant metabolic effect, not a trivial one — fasting glucose and HbA1c belong in the monitoring panel for anyone using tesamorelin, and it matters most for people who already carry metabolic risk.

IGF-1 and the cancer contraindication

Tesamorelin reliably raises IGF-1, and chronically elevated IGF-1 is the reason the GH-axis class carries a firm oncology red line. The label contraindicates tesamorelin in patients with active malignancy and requires that any pre-existing malignancy be inactive and its treatment complete before starting¹. It is also contraindicated in pregnancy and in people with disruption of the hypothalamic-pituitary axis¹. None of this means tesamorelin has been shown to cause cancer — it has not — but raising a growth-promoting hormone in someone with active cancer is an avoidable risk, and the label treats it as absolute. IGF-1 monitoring is part of responsible use.

Serious but uncommon: hypersensitivity

The label notes that hypersensitivity reactions occurred in clinical trials and advises patients to seek immediate medical attention and discontinue the drug if a serious reaction is suspected¹. This is the uncommon-but-important category: most people will only ever experience the mild local and fluid-related effects above, but a genuine allergic reaction is a stop-the-drug event.

Off-label use: where the label stops applying cleanly

Here is the pivot that honest coverage requires. Every rate above was measured in adults with HIV-associated lipodystrophy — the only population tesamorelin is FDA-approved for. When tesamorelin is used off-label for general fat loss, bodybuilding, or anti-aging (as it increasingly is, often via grey-market compounded vials), the side-effect profile is reasonably predicted by the same GH-axis biology, but it has not been formally measured in those users. The label is explicit that the drug is not indicated for weight-loss management and that its long-term cardiovascular safety has not been established¹ — that second point is a genuine gap, not a clean bill of health. For the full accounting of what tesamorelin is and isn't proven to do, see tesamorelin benefits: what the evidence shows, and for how it compares with the compounded GHRH peptide it's most often confused with, see tesamorelin vs sermorelin.

The bottom line

Tesamorelin's side effects are among the best-documented in the GH-peptide category because they sit on a real FDA label: mostly mild injection-site reactions, a characteristic GH-axis fluid-retention cluster (edema, joint aches, carpal tunnel) that is transient or reverses on stopping, a measurable glucose effect (5% vs 1% HbA1c ≥6.5% at 26 weeks) that demands monitoring, a reliable IGF-1 rise that drives an absolute contraindication in active malignancy, and uncommon hypersensitivity reactions¹. The catch is that all of it was measured in HIV lipodystrophy patients over 26 weeks, and long-term cardiovascular safety remains unestablished — so for off-label use the label is the best available map, not a guarantee. This is a monitored prescription drug, not a supplement. For where the broader GHRH-peptide class sits on safety, start with our pillar guide, Sermorelin for Sleep, Recovery & Healthy Aging, see the compounded-peptide parallel in sermorelin side effects, and if you're weighing providers, we rank them in our guide to the best sermorelin providers.